Pharmaceutical manufacturers are also increasingly interested in developing fixed-dosage combinations (FDC) (formulations of two or more active ingredients combined in a single dosage form available in certain fixed doses) offering clinical benefits and/or reduced risk while also improving patient compliance and extending the life cycle of established therapies. PDG Technology™ provides the best tools for the FDC development and production because it sets minimal limitations for the substances to be processed.

PDG Technology™ is the ultimate solution for developing products rapidly - weeks instead of months. Feasibility studies are typically performed within 2-4 weeks and full galenic development in 3 months. Additionally the formulations can be protected due to technology patents of the manufacturing process. This provides you

• Faster galenic development
• Earlier knowledge of difficulties to overcome
• Possibility to evaluate more formulations in shorter time
• Faster market entry